Contact | Print version | PDF version | Send article | RSS feed

Sorbus Pharmaceuticals GmbH incorporated in Vienna, Austria

09 Feb 2010 - Sorbus Pharmaceuticals GmbH announced its incorporation in Vienna, Austria. Sorbus discovers and develops novel treatments for complicated wounds, cancer and other life-threatening diseases. Its lead drug, SertaSil, has demonstrated exceptional effects in patients with acute and chronic wounds and burns. SertaSil speeds up the wound healing process and treats wound infections, including infections by antibiotic resistant bacteria. Initially, Sorbus will develop SertaSil for the treatment of chronic non-healing wounds such as diabetic foot ulcers and venous leg ulcers. Very limited treatment options are available for these patients, and SertaSil will therefore fill an important medical need. Sorbus has received support for the development of SertaSil from the Austria Wirtschaftsservice GmbH (aws).